Patrick M. Gillevet is a Professor and Director of the Microbiome Analysis Center at George Mason University, with a primary appointment in the Biology Department and affiliate faculty status in the School of Systems Biology. His career focuses on integrating genomics, bioinformatics, and molecular ecology to study microbiome interactions in human health and environmental systems, including the development of multitag sequencing for high-throughput microbial analysis. Education: Ph.D., Biochemistry, University of Manitoba (1982) B.S., Microbiology, University of Toronto (1976) His research explores dysbiosis in the human microbiome (gut, mouth, urogenital, respiratory tracts) and its role in diseases, cognitive function, and social behavior. He pioneered the concept of the "metabiome" to describe host-microbiome interactions in systems biology. Key projects include analyzing multitag sequencing for evolutionary studies and microbial community characterization in ecosystems. Recent publications highlight collaborations on gut microbiome trends in cirrhosis, alcohol use disorder, and antibiotic resistance, with a focus on cross-sectional and longitudinal analyses. His work spans clinical trials (e.g., griffithsin gel), dietary interventions, and environmental microbiome studies.
Dr. Jason Yi is an Assistant Professor of Neuroscience at Washington University School of Medicine (WashU Medicine). His research focuses on understanding the molecular pathways that shape nervous system development and function, with particular emphasis on autism spectrum disorders (ASD). He leads the Yi Lab, which investigates the role of the ubiquitin ligase UBE3A in the brain and its implications for neurodevelopmental disorders. Dr. Yi received his BS in Biochemistry and Molecular Biology from Dickinson College in 2001 and his PhD in Pharmacology from Duke University in 2009. His laboratory is broadly interested in the molecular pathways that shape nervous system development and function, with the ultimate goal of understanding how dysfunction in these pathways contributes to disease. The current focus is on autism spectrum disorders (ASD), using genetic information from human patients to guide in vitro and in vivo experiments employing biochemical, genetic manipulation, cell biological, and microscopy techniques. Dr. Yi's research has significant clinical implications, particularly in understanding how UBE3A dysfunction relates to both Angelman syndrome (caused by lack of UBE3A activity) and autism (caused by excessive UBE3A activity). His lab discovered that a single phosphorylation event in UBE3A turns off its ubiquitin ligase activity, and that mutations in this site are linked to autism. This work bridges disease genetics with a mechanistic understanding of ASD neurobiology and aims to define developmental timepoints for ASD onset. Dr. Yi's research has been recognized with numerous prestigious awards: Ruth K. Broad Biomedical Research Foundation Predoctoral Fellowship (2006) F32 Kirschstein National Research Service Award (2011) Christina Castellana Postdoctoral Fellowship (2011-2014) The University of North Carolina Postdoctoral Award for Research Excellence (2015) Bridge to Independence Award, The Simons Foundation (2017) NARSAD Young Investigator Award, Brain and Behavior Research Foundation (2018) Whitehall Foundation Research Grant (2018) Alfred P. Sloan Foundation Research Fellowship (2019) Dr. Yi's research program is supported by significant grant funding from organizations including The Simons Foundation, Brain and Behavior Research Foundation, and the Whitehall Foundation. His work bridges basic molecular neuroscience with clinical implications for neurodevelopmental disorders, particularly autism spectrum disorders. Through his research, Dr. Yi is contributing to a deeper understanding of the molecular mechanisms underlying ASD, which may ultimately lead to new therapeutic approaches and interventions. The Yi Lab maintains a collaborative research environment focused on cutting-edge neuroscience techniques. The lab combines molecular, cellular, and genetic approaches to study UBE3A function and its role in neurodevelopment. Their work utilizes patient-derived genetic information to guide experimental approaches, ensuring clinical relevance to autism spectrum disorders. Dr. Yi is also actively involved in mentoring graduate students and postdoctoral fellows, contributing to the training of the next generation of neuroscientists.
Frida Hållenius is an Associate Professor and Senior Lecturer in Molecular Nutrition at the Division of Food and Pharma, Faculty of Engineering (LTH), Lund University. She is a key member of the LTH Profile Area: Food and Bio and leads or actively participates in multiple research projects exploring the role of diet and gut microbiota in human health. Associate Professor in Molecular Nutrition Senior Lecturer, Division of Food and Pharma Faculty of Engineering (LTH), Lund University Principal Investigator, Gut Microbiome Laboratory (GML) Active researcher in 3 ongoing projects, including NeuroFood and ScanOats Her research is centered on host-microbiota interactions, particularly how dietary components, probiotics, and polyphenols influence gut health, inflammation, metabolic diseases, and neuroinflammation. Her work bridges nutrition, microbiology, and neuroscience, with a strong focus on preventive strategies for lifestyle-related diseases such as obesity, diabetes, and Alzheimer’s disease. She employs both animal models (e.g., C57BL/6, Apoe-/- mice) and human-relevant in vitro systems to study dietary interventions. The recent trends in her publications highlight a strong focus on the gut-brain axis, the impact of Nordic berries and legumes on microbiota and metabolic health, and the use of advanced models like 3D intestinal tissue. Her work often involves interdisciplinary collaboration and contributes to multiple UN Sustainable Development Goals, particularly those related to good health and well-being. Scientific Awards: No specific awards mentioned in the provided text. She has supervised several junior researchers and students, including research students and assistants, and is actively involved in grant-funded research projects from FORMAS and private foundations. She leads the Gut Microbiome Laboratory (GML), a collaborative research environment focused on understanding how diet shapes the gut microbiome and influences disease pathways. Her leadership in projects like NeuroFood and those targeting Alzheimer’s disease underscores her commitment to translational nutritional science.
Dr. Alexandra Piotrowski-Daspit is an Assistant Professor in the Biomedical Engineering department and Internal Medicine – Pulmonary and Critical Care Medicine at the University of Michigan Medical School. She is a chemical/biological engineer with expertise in polymeric biomaterials for gene therapies, focusing on in vivo behavior of delivery vehicles and strategies to optimize biodistribution. Education: Ph.D. in Chemical/Biological Engineering Her research bridges polymer chemistry, gene delivery, and translational medicine, emphasizing in utero interventions and pulmonary targeting. Key areas include nanoparticle surface engineering, macrophage decoys, and computational pharmacokinetic modeling. Recent publications highlight systemic in utero gene editing for cystic fibrosis, poly(amine-co-ester) nanoparticle tunability, and mucosal vaccination platforms. She also explores miRNA therapies for congenital diaphragmatic hernia and triplex-forming PNAs for CFTR correction. PhRMA Foundation Awardee (2024) Her work involves interdisciplinary collaborations, DEI initiatives, and translational projects from postdoc foundations in W. Mark Saltzman’s lab. Labs like Saltzman and SCGE teams support her research.
Gary Gibson is a tenured Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Burke Neurological Institute . He leads the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration , focusing on age-related neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease . Educational background: Ph.D. in Physiology (Biochemistry/Neuroscience), Cornell University B.S. in Zoology and Chemistry, University of Wyoming His research investigates how mitochondrial dysfunction , reduced glucose metabolism , and oxidative stress contribute to neurodegeneration. He explores therapeutic interventions targeting these mechanisms, including benfotiamine for improving thiamine levels and modulating post-translational modifications of mitochondrial enzymes like the α-ketoglutarate dehydrogenase complex (KGDHC) . These studies integrate human autopsy samples, genetically modified cells , and transgenic mouse models to test hypotheses about calcium dysregulation, free radical damage, and inflammatory cascades. Recent publications highlight his work on mitochondrial enzyme plasticity , nutritional metabolism in dementia, and benfotiamine's neuroprotective effects in clinical trials. He has secured continuous NIH funding (Grant R01AG043679) and holds three U.S. patents . Dr. Gibson serves on editorial boards for Neurochemical Research , Neurochemical International , and Journal of Neurochemistry , and has mentored undergraduate students and postdoctoral researchers .
Trond Vidar Hansen is a Professor at the Department of Pharmacy, University of Oslo , and leads the LIPCHEM research group . He collaborates with institutions including the University of Bergen and Vestlandets Innovasjonsselskap through the VITADEL project, which recently received NOK 5,000,000 in verification support from the Research Council of Norway. His research focuses on the synthesis and biological evaluation of specialized pro-resolving lipid mediators derived from omega-3 fatty acids, with applications in inflammation resolution, neuroinflammation, and drug development. University : University of Oslo Department : Department of Pharmacy Research Group : LIPCHEM Collaborations : University of Bergen, Vestlandets Innovasjonsselskap Research Interests : H Hansen's work centers on the organic synthesis of bioactive lipid derivatives, particularly pro-resolving mediators from omega-3 polyunsaturated fatty acids. His team investigates their roles in inflammatory disease models , neuroinflammation , and PPAR receptor activation , aiming to develop therapeutic agents for conditions like chronic pain, diabetes, and neurodegenerative disorders. The research integrates stereoselective chemistry , biochemical profiling , and pharmacological evaluation to validate these mediators' clinical potential. Recent Awards : 2025: NOK 2,000,000 verification support from Research Council of Norway 2025: Co-leader of NOK 5,000,000 VITADEL project Publications : His articles (2015–2024) reveal a focus on stereoselective synthesis of resolvins, protectins, and maresins, with applications in anti-inflammatory and neuroprotective therapies . Key subfields include omega-3 metabolite profiling , PPAR agonist design , and biosynthetic pathway elucidation , often utilizing human cell models and mouse disease models . Collaborative projects emphasize commercialization of academic research and translational medicine .
Dr. Craig R. Forest is a Professor at the Georgia Institute of Technology's Woodruff School of Mechanical Engineering, specializing in bioMEMS, neuroengineering, and high-throughput instrumentation. He leads the Precision Biosystems Laboratory, focusing on developing robotic tools for neuroscience and genomics. His research bridges mechanical engineering with biological systems, creating innovations like the PatcherBot for automated electrophysiology. Forest earned his Ph.D. (2007) and M.S. (2003) from MIT and B.S. (2001) from Georgia Tech. He has been recognized with awards including the 2013 Georgia Tech Class of 1940 W. Roane Beard Outstanding Teacher Award and Engineer of the Year (2013). His work emphasizes interdisciplinary collaboration, particularly through initiatives like CREATE-X and the Invention Studio, fostering student entrepreneurship and maker culture. Key contributions include ultra-high-throughput genomics tools, microfluidic systems, and acoustic reporter genes for medical imaging. Forest’s lab explores emerging fields like intracellular robotics in neuroscience and molecular communication networks, with applications in drug discovery and personalized medicine. Scientific awards highlight his impact in education and engineering innovation. His grants and collaborations span academic and industrial partnerships, advancing both theoretical and applied research in bioengineering and nanotechnology.
Kuo-Fen Lee, PhD is a Professor at the Salk Institute for Biological Studies, holding the prestigious Helen McLoraine Chair of Molecular Neurobiology. He leads the Clayton Foundation Laboratories for Peptide Biology, where his research focuses on nerve regeneration, spinal cord injury, and molecular mechanisms underlying neural development and neurodegenerative diseases. His work bridges basic neuroscience with potential therapeutic applications for conditions like ALS, paralysis, and Alzheimer's disease. Dr. Lee received his educational training from multiple prestigious institutions: a degree in Plant Pathology from National Taiwan University; an MS in Cancer Enzymology and Cell Differentiation from National Yang-Ming Medical College, Taiwan; a PhD in Endocrinology from Baylor College of Medicine, Houston; and completed his postdoctoral training at the Whitehead Institute for Biomedical Research. His primary research interests center on understanding why humans cannot regenerate damaged nerves while many other animals can. Dr. Lee has made significant discoveries regarding the p45 protein, which promotes nerve regrowth in mice but is absent in humans (who instead have p75, which inhibits nerve growth). His laboratory also studies neuregulin signaling, neuromuscular synapse formation, and the role of various proteins like nestin in neural development and maintenance. His work often employs mouse models to investigate spinal cord injury, pain pathways, and neurodegenerative conditions. Analysis of Dr. Lee's recent publications reveals a consistent focus on molecular neurobiology with particular emphasis on neural signaling pathways, synaptic maintenance, and nerve regeneration mechanisms. His research spans from basic molecular mechanisms to potential therapeutic applications, with increasing attention to pain pathways, Alzheimer's disease models, and the intersection of neuroscience with immunology and metabolism in recent years. As holder of the Helen McLoraine Chair of Molecular Neurobiology, Dr. Lee has received significant institutional recognition for his contributions to neuroscience. While specific awards aren't detailed in the provided text, his sustained funding and leadership position indicate substantial peer recognition in his field. Dr. Lee's research program involves extensive collaboration with other neuroscience laboratories, as evidenced by his numerous co-authored publications across various neuroscience subdisciplines. His work has been consistently funded, allowing for the maintenance of an active research laboratory focused on nerve regeneration and molecular neurobiology. The Clayton Foundation Laboratories for Peptide Biology serves as the primary research environment for Dr. Lee's team, where they investigate molecular mechanisms of nerve development, regeneration, and degeneration using advanced genetic, molecular, and cellular approaches. The laboratory maintains active research programs in multiple areas of neural signaling and development.
Andrew J. Todd is a Professor and Honorary Fellow in the School of Psychology & Neuroscience at the University of Glasgow. His research focuses on neurochemistry and synaptic connections in the mammalian spinal cord, particularly the organization of neuronal circuits underlying pain and itch perception. He employs techniques like immunocytochemistry, confocal microscopy, and electron microscopy. Collaborations include researchers from institutions such as UCL, Saga University, and the University of Pittsburgh. His work is funded by the Wellcome Trust and BBSRC. Roles: Professor, Honorary Fellow Affiliations: School of Psychology & Neuroscience, University of Glasgow Research Interests Dr. Todd investigates spinal dorsal horn circuits, including projection neurons, interneurons, and synaptic plasticity. Key topics include: Neurochemical characterization of spinal neurons Role of neuropeptides like substance P and gastrin-releasing peptide Mechanisms of neuropathic pain and spinal circuit adaptations Functional roles of specific neuron populations in laminae I-III Articles Overview Recent work includes studies on spinal projection neuron markers (e.g., Tacr1, Gpr83), synaptic circuits involving GRP-expressing neurons, and interneuron subtypes' roles in pain/itch. Notable findings include the absence of neuronal loss in neuropathic pain models and the identification of novel spinal circuits. Grants & Funding Funded by the Wellcome Trust and BBSRC . Collaborations span international institutions, emphasizing spinal neurobiology and sensory processing.
Dr. Jonathan Bones is an Associate Professor in the School of Chemical and Bioprocess Engineering at University College Dublin (UCD) and Principal Investigator of the Characterisation and Comparability Group at NIBRT. His research focuses on analytical methods for biopharmaceuticals, including liquid chromatography-mass spectrometry (LC-MS) for protein characterization, glycomics, and process optimization. He holds a BSc and PhD in Analytical Chemistry from Dublin City University. His work has been recognized through inclusion in the Medicine Maker Power List. He leads a team of 18 researchers, supported by SFI, EI, and industry partnerships. Education: BSc in Analytical Science (Chemistry), Dublin City University PhD in Analytical Chemistry, Dublin City University Research Interests: Development of advanced LC-MS platforms for glycomics, proteomics, and bioprocess analysis. Key areas include: Quantitative proteomics/metabolomics for bioprocess monitoring Liquid phase separations for complex bioanalysis Process analytical technology (PAT) His group collaborates with ThermoFisher Scientific on analytical workflows for biopharmaceutical characterization. Articles Trends: Recent work emphasizes analytical methods for AAV vector characterization, biosimilar comparability via MAM/iMAM, and process clearance of excipients. Over 126 publications highlight his contributions to biopharmaceutical quality control and process understanding. Awards: Medicine Maker Power List (2023): Top 100 influential scientists in biopharmaceutical manufacturing and analysis Advising & Grants: Supervises PhD students in bioprocessing and analytical chemistry Funding from Science Foundation Ireland (SFI), Enterprise Ireland (EI), and EU FP7 Industry collaborations with ThermoFisher Scientific and Bristol Myers Squibb Labs & Teams: Leads the Characterisation and Comparability Lab at NIBRT, focused on cutting-edge analytical tools for bioprocess development and product quality assurance.
Professor Dario Alessi is a leading academic at the University of Dundee's School of Life Sciences, serving as the Director of the MRC Protein Phosphorylation Unit (MRC PPU) and Professor of Signal Transduction. He earned his BSc (1988) and PhD (1991) from the University of Birmingham. His research focuses on protein phosphorylation and ubiquitylation pathways, particularly the LRRK2 kinase pathway linked to Parkinson's disease. He has made groundbreaking contributions to understanding LRRK2's role in neurodegeneration, including its interaction with Rab proteins and scaffolding molecules like RILPL1. School of Life Sciences, University of Dundee MRC PPU Director since 2012 Signal Transduction Therapy Unit Director His work combines molecular biology, biochemistry, and collaborative industry partnerships to advance therapeutic strategies for Parkinson's disease. Key research areas include LRRK2 activation mechanisms, Rab protein phosphorylation, and lysosomal dysfunction. Alessi has trained over 30 graduate students and 40 postdocs, many now in academic and industry leadership roles. Notable awards include the EMBO Gold Medal (2005), the Robert A. Pritzker Prize for Leadership in Parkinson’s Research (2023), and an OBE (2023) for contributions to medical science. His lab promotes open science, sharing reagents and protocols globally through platforms like MRC Pure Agents and LRRK2.bio. Current projects include investigating novel mitochondrial and organelle biology in Parkinson’s, developing biomarkers, and advancing LRRK2 inhibitors through clinical trials. Collaborations span the Michael J. Fox Foundation, Aligning Science Across Parkinson’s, and the UK Dementia Research Initiative.
Noelia Fernández Castillo is a Lecturer at the University of Barcelona's Faculty of Biology, affiliated with the Department of Genetics, Microbiology, and Statistics. She leads the Human Molecular Genetics research group and holds roles in academia spanning education and research. Education: Bachelor's/Master's in Genetics (University of Barcelona, 2004) Experimental Biology Master's (2006) Teaching Certification (2005) PhD in Biology (2011) Research focuses on genetic mechanisms underlying psychiatric disorders, addiction, and neurodevelopmental conditions. Key areas include epigenetic influences on ADHD, genetic contributions to aggression, and molecular pathways in substance use disorders. Uses animal models (zebrafish, mice) and human genomic data to explore these topics. Notable projects include studying nutrition's impact on impulsive behaviors (Eat2beNICE project, 2017-2022) and investigating shared genetic susceptibility between addictions and aggression. Current work emphasizes genetic pleiotropy in ADHD and psychiatric comorbidity. Has led/co-led grants from the European Union, Spanish Ministry of Health, and Ministry of Science. Active in collaborative research with institutions across Europe and North America.
Maria Golson, PhD, is an Assistant Professor of Medicine in the Division of Endocrinology, Obesity and Metabolism at the Johns Hopkins School of Medicine. She joined the institution in 2020 and leads research focused on the intrinsic and extrinsic regulation of beta-cell function and insulin secretion. Her work is central to understanding pancreatic endocrine cell development and its implications in diabetes. Education: B.S. in Biology (Genetics concentration), Duke University, 2000 Ph.D. in Cell and Molecular Biology (Genetics and Gene Regulation), University of Pennsylvania, 2008 Postdoctoral Training, Vanderbilt University Dr. Golson's research spans molecular mechanisms of beta-cell function, epigenetic regulation in diabetes, and single-cell analysis of pancreatic islets. She employs advanced genomic and epigenomic tools to explore cellular states in both type 1 and type 2 diabetes, with a focus on identifying pathways that could be targeted for regeneration or functional enhancement of insulin-producing cells. Her recent publications, appearing in journals such as Nature Metabolism and Diabetes , reflect a strong trend toward multiomics and single-cell technologies to uncover novel cellular states in human islets. These studies integrate transcriptomics, epigenetics, and functional validation to dissect disease mechanisms. Dr. Golson has been supported by institutional affiliations and collaborations, including membership in the HPAP Consortium and the American Diabetes Association. While no formal awards are listed, her publication record indicates significant scientific contributions. She has mentored researchers through collaborative projects, though no formal advisees are named. Her lab engages in interdisciplinary research involving genetics, molecular biology, and bioinformatics to advance diabetes therapeutics.
Feyruz V. Rassool is a Professor at the University of Maryland School of Medicine, with primary appointment in Radiation Oncology. She serves as Co-director of the Experimental Therapeutics Program at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) and holds an adjunct Associate Professor position at VARI’s Center for Epigenetics. Her research focuses on DNA damage/repair pathways in cancer, particularly their therapeutic exploitation through PARP and DNMT inhibitors. Education: B.Sc. in Human Genetics (1983, University College London), Ph.D. in Biological Sciences (1990, Royal Postgraduate Medical School) Postdoctoral Training: University of Chicago (1990-1994) Her work explores the intersection of DNA repair , epigenetics , and mitochondrial dysfunction to develop novel therapies for breast, ovarian, lung, and leukemias. Key projects include STING-dependent interferon signaling , pathogen mimicry in cancer cells, and metastasis suppression through PARPi/epigenetic combinations. Dr. Rassool is part of the SU2C Epigenetics Dream Team and has secured multiple grants from NCI, NIH, and the Adelson Medical Research Foundation. Her recent preclinical studies with PARP/DNMT inhibitors are being translated into Phase I/II trials for AML and TNBC. Scientific Awards Ziskin Award (2012) NCI-SPORE Grant Co-Leader NIH/NCI P30 CA134274 Support Grant She has mentored 13 PhD/postgraduate researchers and collaborates on clinical trials with Pfizer, VARI-SU2C, and ASTRO. Her lab employs techniques like DNA repair assays , RNAseq , and mouse xenograft models to investigate mechanisms of action for epigenetic drugs.
Brandon Weissbourd is an Assistant Professor in the Biology department at the Massachusetts Institute of Technology (MIT) and holds a joint appointment as an Investigator at the Picower Institute for Learning and Memory. He joined MIT in 2023 after completing a postdoctoral fellowship in the lab of David Anderson at the California Institute of Technology (Caltech). Prior to that, he earned his PhD in Biology from Stanford University in 2016 under the mentorship of Liqun Luo, and a BA in Human Evolutionary Biology from Harvard University in 2009. His research interests encompass systems neuroscience, evolutionary biology, and molecular biology. He uses jellyfish models, such as Clytia hemisphaerica, to study the evolution and functional mechanisms of nervous systems. His work combines computational techniques like single-cell RNA-seq and advanced microscopy with traditional genetic and anatomical approaches to dissect neural circuits and their roles in behaviors like feeding and social interaction. Additionally, he has explored serotonin and noradrenaline systems in mammals, focusing on their heterogeneity and functional connectivity. Recent publications emphasize the utility of non-traditional model organisms for evolutionary studies and underscore his expertise in computational methods for neurobiological analysis. Earlier work includes groundbreaking studies on the dorsal raphe serotonin system and basal forebrain circuits governing sleep-wake cycles. No scientific awards or honors have been explicitly mentioned in the provided text. Weissbourd’s academic trajectory reflects a strong emphasis on interdisciplinary research, merging evolutionary, molecular, and systems-level perspectives to understand neural systems across species. His advising record is not detailed here, though he has been affiliated with prestigious research labs during his training. Current affiliations include the MIT Biology department and the Picower Institute, where he likely contributes to collaborative projects in systems and evolutionary neuroscience. Weissbourd’s work is grounded in experimental models such as Clytia medusa and mouse brain studies, enabling him to investigate both ancient nervous system architectures and modern mammalian neural pathways. His lab’s focus on functional genomics and circuit mapping positions him at the forefront of studies on neural diversity and evolutionary innovation.
